MA46743A - Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v - Google Patents

Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v

Info

Publication number
MA46743A
MA46743A MA046743A MA46743A MA46743A MA 46743 A MA46743 A MA 46743A MA 046743 A MA046743 A MA 046743A MA 46743 A MA46743 A MA 46743A MA 46743 A MA46743 A MA 46743A
Authority
MA
Morocco
Prior art keywords
inhibitors
integrin alpha
propionic acids
acids substituted
substituted
Prior art date
Application number
MA046743A
Other languages
English (en)
French (fr)
Inventor
Palanikumar Balasubramanian
Rita Civiello
Pratik Devasthale
Suresh Dhanusu
Leatte R Guernon
Xiaojun Han
Swanee E Jacutin-Porte
Michael F Parker
Kumaravel Selvakumar
Xiang-Yang Ye
Guohua Zhao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46743A publication Critical patent/MA46743A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA046743A 2016-11-08 2017-11-07 Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v MA46743A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08

Publications (1)

Publication Number Publication Date
MA46743A true MA46743A (fr) 2019-09-18

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046743A MA46743A (fr) 2016-11-08 2017-11-07 Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v

Country Status (30)

Country Link
US (2) US10968219B2 (enExample)
EP (1) EP3538525B1 (enExample)
JP (1) JP7097358B2 (enExample)
KR (1) KR102505629B1 (enExample)
CN (1) CN110167935B (enExample)
AR (1) AR110153A1 (enExample)
AU (1) AU2017359023B2 (enExample)
CL (1) CL2019001264A1 (enExample)
CO (1) CO2019005824A2 (enExample)
CY (1) CY1125496T1 (enExample)
DK (1) DK3538525T3 (enExample)
EA (1) EA038164B1 (enExample)
ES (1) ES2925173T3 (enExample)
HR (1) HRP20220990T1 (enExample)
HU (1) HUE059708T2 (enExample)
IL (1) IL266473B (enExample)
LT (1) LT3538525T (enExample)
MA (1) MA46743A (enExample)
MX (1) MX380799B (enExample)
MY (1) MY199931A (enExample)
NZ (1) NZ754207A (enExample)
PE (1) PE20191647A1 (enExample)
PL (1) PL3538525T3 (enExample)
PT (1) PT3538525T (enExample)
RS (1) RS63483B1 (enExample)
SI (1) SI3538525T1 (enExample)
SM (1) SMT202200338T1 (enExample)
TW (1) TWI763733B (enExample)
WO (1) WO2018089353A1 (enExample)
ZA (1) ZA201903665B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110167934B (zh) * 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
PT3538525T (pt) * 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
AU2017359028A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CN109824495B (zh) * 2019-02-02 2022-12-09 盐城师范学院 一种新型偶联反应在制备碳-碳键结构化合物中的应用
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
KR20230128471A (ko) * 2020-12-04 2023-09-05 에우불루스 바이오테라퓨틱스 인코포레이티드 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용
IL327186A (en) * 2023-09-21 2026-05-01 Morphic Therapeutic Inc Human α5β1 integrin inhibition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
EP1047425A4 (en) * 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
MXPA05006588A (es) * 2002-12-20 2005-08-16 Pharmacia Corp Compuestos de pirazol como derivados antagonistas del receptor de la integrina.
BR0317600A (pt) * 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
JP2013503834A (ja) 2009-09-04 2013-02-04 ビーエーエスエフ ソシエタス・ヨーロピア １−フェニルピラゾールの製造方法
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) * 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
PT3538525T (pt) * 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina

Also Published As

Publication number Publication date
WO2018089353A1 (en) 2018-05-17
RS63483B1 (sr) 2022-09-30
MX380799B (es) 2025-03-12
AU2017359023B2 (en) 2021-12-09
ES2925173T3 (es) 2022-10-14
TWI763733B (zh) 2022-05-11
US20190263808A1 (en) 2019-08-29
SI3538525T1 (sl) 2022-09-30
PT3538525T (pt) 2022-08-16
AR110153A1 (es) 2019-02-27
JP2019537594A (ja) 2019-12-26
EA038164B1 (ru) 2021-07-16
US20210188847A1 (en) 2021-06-24
US11884661B2 (en) 2024-01-30
KR20190073554A (ko) 2019-06-26
PL3538525T3 (pl) 2022-09-12
MX2019005244A (es) 2019-08-05
NZ754207A (en) 2025-09-26
ZA201903665B (en) 2022-12-21
SMT202200338T1 (it) 2022-09-14
US10968219B2 (en) 2021-04-06
JP7097358B2 (ja) 2022-07-07
EP3538525A1 (en) 2019-09-18
PE20191647A1 (es) 2019-11-07
HUE059708T2 (hu) 2022-12-28
LT3538525T (lt) 2022-09-26
TW201823244A (zh) 2018-07-01
DK3538525T3 (da) 2022-08-29
CN110167935B (zh) 2022-05-27
CY1125496T1 (el) 2026-02-25
EP3538525B1 (en) 2022-06-22
CA3042707A1 (en) 2018-05-17
AU2017359023A1 (en) 2019-06-20
CL2019001264A1 (es) 2019-09-13
IL266473A (en) 2019-07-31
KR102505629B1 (ko) 2023-03-02
CN110167935A (zh) 2019-08-23
MY199931A (en) 2023-11-29
HRP20220990T1 (hr) 2022-11-11
CO2019005824A2 (es) 2019-06-11
IL266473B (en) 2022-06-01
EA201991122A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
CY1125496T1 (el) 3-υποκατεστατημενα προπιονικα οξεα ως αναστολεις αλφα v ιντεγκρινης
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46746A (fr) Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3414327A4 (en) PROOF OF NUCLEIC ACIDS
MA40775A (fr) Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
EP3687543A4 (en) COMBINATION PHARMACEUTICAL DRUGS AS RSV INHIBITORS
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3630748A4 (en) SMALL MOLECULAR IRE1 INHIBITORS
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3433382A4 (en) SYNTHETIC NUCLEIC ACID SPIKE INS
EP3435941A4 (en) DETECTION OF MICROBIAL INFECTION IN WOUNDS
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3416964A4 (en) Carboxamide derivatives as RSK inhibitors
EP3393608A4 (en) PLANARE SOLUTIONS FOR OBJECT PURPOSE PROBLEMS
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
EP3386981A4 (en) HETEROCYCLES SUITABLE AS ANTICROGEN
EP3422155A4 (en) OBJECT CONTROLLER
EP3543772A4 (en) REFLECTIVE DISPLAY DEVICE